Intravitreal bevacizumab for macular edema due to occlusive vasculitis

Seminars in Ophthalmology

Volumn 22, Issue 2, 2007, Pages 105-108

  Margolis, Ron ^a   Lowder, Careen Y ^a   Sears, Jonathan E ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bevacizumab; Macular edema; Occlusive vasculitis; Retinal ischemia; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CONNECTIVE TISSUE DISEASE; FEMALE; HUMAN; PRIORITY JOURNAL; RETINA FOVEA; RETINA ISCHEMIA; RETINA MACULA EDEMA; VASCULITIS; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FUNDUS OCULI; HUMANS; INJECTIONS; MACULAR EDEMA, CYSTOID; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULITIS; VISUAL ACUITY; VITREOUS BODY;

EID: 34250376762     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530701420074     Document Type: Article

References (5)

1. Perez VL, Chavala SH, Ahmed M, Chu D, Zafirakis P, Baltatzis S, Ocampo V, Foster CS. Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol. 2004; 49:399-418.
2. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26:999-1005.
3. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO Study. Retina 2007; 27:141-9.
4. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006 Nov; 90(11):1344-9.
5. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist. 2004; 9 S1:11-8.